Imaging HER2-positive metastatic esophagogastric cancer with 89Zr-trastuzumab PET and 18F-FDG PET.

Melissa A. Lumish,Steven Brad Maron,Viktoriya Paroder,Steven Philemond,Joseph A. O’Donoghue,Heiko Schöder,Jason S. Lewis,Yelena Y. Janjigian,Neeta Pandit-Taskar

Imaging HER2-positive metastatic esophagogastric cancer with 89Zr-trastuzumab PET and 18F-FDG PET.

2021

Melissa A. Lumish
Steven Brad Maron
Viktoriya Paroder
Steven Philemond
Joseph A. O’Donoghue
Heiko Schöder
Jason S. Lewis
Yelena Y. Janjigian
Neeta Pandit-Taskar

4068Background: Variations in HER2 expression between primary tumor and metastases may contribute to drug resistance in HER2-positive mEG cancer. Whole body imaging with 89Zr-trastuzumab PET has a ...

Keywords:

Whole body imaging
Oncology
Medicine
89Zr-trastuzumab
Cancer
Internal medicine
Drug resistance
her2 expression
Primary tumor
18f fdg pet
esophagogastric cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations